Defensive injectables and packaging caught a bid while tools and glass slipped; West Pharmaceutical faded 8% after its earnings-day pop, days before 100% pharma tariffs land.

Baxter led the vertical, up 3.4% to $22.40 — the sterile-injectables chokepoint, whose IV solutions and drug-delivery systems sit at the center of chronic US shortage economics, catching a defensive-healthcare bid on a risk-off day. There was no fresh news; Baxter reports Q2 on July 30, and Friday was rotation into a cheap, essential-products name. AptarGroup (up 2.6% on drug packaging and delivery) and ICU Medical (up 2.6% on infusion and sterile injectables) rose alongside it.

West Pharmaceutical was the laggard, down 7.7% to $328.20, in a beat-and-fade. West reported Q2 net sales of $872.3M (up 13.8%) and adjusted EPS of $2.37 (up 28.8%), beating by roughly $0.29, and raised full-year guidance to $8.85–9.05 adjusted EPS on $3.345–3.38B of revenue. The stock had surged to a high on the print, then gave it back Friday on profit-taking. West owns the drug-contact-components chokepoint — the elastomer stoppers and seals on nearly every injectable vial — so the sell was valuation and positioning, not demand.

The analytical-tools and glass tiers were the soft spot. Corning fell 6.0% to $146.65 — the pharma-glass name behind Valor vials — sliding into its July 28 print; Repligen dropped 4.1% to $131.96 on the bioprocessing-resin line and Maravai 4.1% to $6.76, both falling with the growth complex, while Waters eased 2.0% ahead of its first quarter as the combined Waters/BD entity. The large-cap drug names were a mild offset, with Novo Nordisk up 1.2% and Eli Lilly up 0.9%.

The calendar is heavy and it ends on policy. Danaher and Corning report July 28, Samsung Biologics July 29, and Mettler-Toledo and Baxter July 30 — but the hard catalyst is July 31, when Section 232 pharmaceutical tariffs (100% on patented pharma and APIs) take effect. That single date reprices every chokepoint this vertical maps — API reshoring, CDMO capacity, fill-finish and glass — by making imported drug supply structurally more expensive. The prints are noise around it; the tariff is the signal.